Moberg Pharma AB (publ) (STO:MOB)

Market Cap	533.14M +29.7%
Revenue (ttm)	16.76M +35.8%
Net Income	-21.62M
EPS	-0.46
Shares Out	47.18M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	66,294
Open	11.44
Previous Close	11.30
Day's Range	11.40 - 11.70
52-Week Range	7.53 - 14.12
Beta	1.09
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 12, 2026

About Moberg Pharma AB

Moberg Pharma AB (publ), a pharmaceutical company, develops and commercializes medical products primarily in Sweden. It offers MOB-015 for the treatment of nail fungus under the Terclara brand. The company was formerly known as Moberg Derma AB (publ) and changed its name to Moberg Pharma AB (publ) in May 2013. It has license agreement with Karo Healthcare for distribution in European market. Moberg Pharma AB (publ) was incorporated in 2006 and is based in Bromma, Sweden.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2006
• Employees: 5
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: MOB

Financial Performance

In 2025, Moberg Pharma AB's revenue was 13.54 million, an increase of 37.99% compared to the previous year's 9.81 million. Losses were -27.24 million, -89.32% less than in 2024.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 25, 2026

Data Sources Report a data error